AR114854A1 - METHODS FOR THE TREATMENT OF CANCER - Google Patents
METHODS FOR THE TREATMENT OF CANCERInfo
- Publication number
- AR114854A1 AR114854A1 ARP190101136A ARP190101136A AR114854A1 AR 114854 A1 AR114854 A1 AR 114854A1 AR P190101136 A ARP190101136 A AR P190101136A AR P190101136 A ARP190101136 A AR P190101136A AR 114854 A1 AR114854 A1 AR 114854A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- mpn
- mdm2 inhibitor
- treating
- compound
- Prior art date
Links
Abstract
Se describen métodos terapéuticos y composiciones farmacéuticas para tratar el cáncer, que incluye una neoplasia mieloproliferativa (MPN), que incluye policitemia vera (PV), trombocitemia esencial (ET) y mielofibrosis primaria en un sujeto humano. En ciertas formas de realización, la presente incluye métodos terapéuticos para tratar una MPN utilizando un inhibidor de MDM2 de fórmula (1) o fórmula (2). Reivindicación 1: Un método para tratar una neoplasia mieloproliferativa (MPN) que comprende la etapa de administrar a un sujeto humano que lo necesite una cantidad terapéuticamente eficaz de un inhibidor de MDM2, en donde el inhibidor de MDM2 es un compuesto de fórmula (1) o fórmula (2) o un compuesto de fórmula (2), o una sal farmacéuticamente aceptable del mismo.Therapeutic methods and pharmaceutical compositions are described for treating cancer, including a myeloproliferative neoplasia (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis in a human subject. In certain embodiments, the present includes therapeutic methods for treating MPN using an MDM2 inhibitor of formula (1) or formula (2). Claim 1: A method for treating a myeloproliferative neoplasia (MPN) comprising the step of administering to a human subject in need thereof a therapeutically effective amount of an MDM2 inhibitor, wherein the MDM2 inhibitor is a compound of formula (1) or formula (2) or a compound of formula (2), or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664673P | 2018-04-30 | 2018-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114854A1 true AR114854A1 (en) | 2020-10-21 |
Family
ID=73042415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101136A AR114854A1 (en) | 2018-04-30 | 2019-04-30 | METHODS FOR THE TREATMENT OF CANCER |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR114854A1 (en) |
-
2019
- 2019-04-30 AR ARP190101136A patent/AR114854A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019007810A2 (en) | Amino-triazolopyridine compounds and their use in the treatment of cancer | |
| MX2020008258A (en) | Pediatric niraparib formulations and pediatric treatment methods. | |
| CO2020015758A2 (en) | Purinone compounds and their use in the treatment of cancer | |
| CO2021015318A2 (en) | Compounds and methods for the treatment of covid-19 | |
| BR112018001640A2 (en) | combination of pd-1 antagonist with an egfr inhibitor | |
| UY36207A (en) | SYK INHIBITORS | |
| CL2020002512A1 (en) | Treatment of hidradenitis suppurativa using jak inhibitors. | |
| CR20140086A (en) | COMBINATION TREATMENTS FOR HEPATITIS C | |
| CO2018004206A2 (en) | Pharmaceutical formulation for oral administration comprising a compound of 25-hydroxy vitamin d " | |
| AR108889A1 (en) | COMBINATIONS FOR CANCER TREATMENT | |
| CL2021003034A1 (en) | Methods of treatment of sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| CL2021003032A1 (en) | Methods of treating chronic spontaneous urticaria using a Bruton's tyrosine kinase inhibitor. | |
| CO2020014599A2 (en) | Methods to treat cancer | |
| UY38228A (en) | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | |
| CO2019007879A2 (en) | Crystalline forms of tebipenem pivoxil, compositions including them, manufacturing methods, and methods of use | |
| RU2018107930A (en) | TLR4 AGONISTS, THEIR COMPOSITIONS AND USE FOR TREATMENT OF CANCER | |
| CL2020000271A1 (en) | Therapeutic combination of an egfr tyrosine kinase inhibitor and a cyclin-dependent kinase inhibitor. | |
| CL2020000270A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor. | |
| CL2022000781A1 (en) | Medicinal cognitive treatments | |
| AR103118A1 (en) | ANAMORELINE-BASED MEDICAL TREATMENTS | |
| MX2020004513A (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same. | |
| CO2023014650A2 (en) | Dosage and administration of recombinant l-asparaginase | |
| CR20220250A (en) | METHODS FOR THE TREATMENT OF DEPRESSIVE DISORDERS | |
| EA201991069A1 (en) | COMBINED THERAPY INHIBITOR OF PHOSPHOINOSITIDE-3-KINASE AND BINDING ZINC AGENT | |
| AR114854A1 (en) | METHODS FOR THE TREATMENT OF CANCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |